Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. (NY: SNY )

43.41 USD UNCHANGED
Last Price Updated: 5:16 PM EST, Dec 31, 2018 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Sanofi-Aventis S.A.

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
The Daily Biotech Pulse: Sanofi, Regeneron Drop COVID-19 Study, 2 Positive AstraZeneca Catalysts, Brickell Awarded Japanese Patent
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) 10X Genomics Inc (NASDAQ: TXG) Acutus Medical Inc (NASDAQ: ... 
Tags FBIO Earnings GSK
From Benzinga
A Peek Into The Markets: US Stock Futures Edge Higher Following August's Rally; Manufacturing Data In Focus
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and the S&P 500 recorded their ... 
Tags Market News Markets AZN
From Benzinga
Sanofi, Regeneron Rheumatoid Arthritis Drug Proves Ineffective Against COVID-19
Sanofi SA (NASDAQ: SNY) announced Tuesday that its rheumatoid arthritis drug Kevzara, developed in partnership withRegeneron ... 
Tags General GSK REGN
From Benzinga
Pharmaceutical Companies Are Doing Much More Than Battling COVID-19
The merger of Pfizer's Upjohn business with Mylan NV(NASDAQ: MYL), along with the potential of its COVID-19 vaccine candidate ... 
Tags SNY JNJ REGN
From Benzinga
A Divergence Has Occurred In Healthcare
For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech. In the ... 
Tags Benzinga ETFs MRNA
From Benzinga
Has The COVID-19 Vaccine Stock Bubble Burst?
COVID-19 vaccine stocks have gotten slammed this month. 
Tags HTBX VXRT MRNA
From Motley Fool
3 Popular Robinhood Stocks Still Worth Buying With the Market at an All-Time High
It's not too late at all to scoop up shares of these Robinhood favorites. 
Tags SNY BRK/B AAPL
From Motley Fool
Top Coronavirus Vaccine Maker Is Yielding More Than Double The S&P
Among best dividend stocks is top coronavirus vaccine candidate AbbVie. The company pays an annualized dividend of $4.72 per share for a yield of about 5%. 
From Investor's Business Daily
Where Will Vaxart Be in 1 Year?
The coronavirus vaccine stock's roller-coaster ride will continue. 
Tags VXRT Market News MRNA
From Motley Fool
These 5 Healthcare Stocks Are the Biggest Winners in 2020
It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus. 
Tags Market News NVAX ALT
From Motley Fool
These 5 Stocks Are The Biggest S&P 500 Healthcare Winners of 2020
Some of the names on this list may surprise you. 
Tags IDXX RHHB/Y SNY
From Motley Fool
3 Stocks to Buy Ahead of the Next Market Crash
These companies are all trading at cheap multiples relative to their earnings. 
Tags VZ SNY GSK
From Motley Fool
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
Wall Street has been on a stellar ride since hitting its bottom in late March. 
Tags Capital & Industrial Goods Stocks / Equities Services
From Blogs - TalkMarkets
Vaxart Stock: Should You Buy the Dip?
Shares of this company, which is making a COVID-19 vaccine in pill form, sell for less than half their peak. 
Tags VXRT NVAX Market News
From Motley Fool
Got $1,000? These Dirt-Cheap Stocks Are Practically Free
These rough and tumble coronavirus stocks could help fund your retirement. 
Tags GSK SNY BNTX
From Motley Fool
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ... 
Tags Market News Biotechnology CRON
From Benzinga
CureVac and EU in advanced talks for 225 million Covid-19 vaccine doses
Shares of CureVac NV soared Thursday after the German biotech firm said it was in advanced talks for the supply of at least 225 million doses of a potential Covid-19 vaccine to EU member states. 
Tags Biotechnology Pharmaceuticals Medical Products
From MarketWatch
Hot Biotech IPO Latest To Gain In Coronavirus Vaccine Race
Tiny CureVac, which popped in its IPO on Friday, announced Thursday it's close to inking a big contract with the European Commission for its coronavirus vaccine candidate. CVAC stock jumped. 
From Investor's Business Daily
Johnson & Johnson To Acquire Momenta Pharmaceuticals For $6.5 Billion
Johnson & Johnson will buy Momenta Pharmaceuticals for $6.5 billion to broaden its reach in treating autoimmune and rare diseases. 
From Investor's Business Daily
The Daily Biotech Pulse: Poseida's Phase 1 Study Placed On Clinical Hold, Orphan Drug Designation For Krystal Biotech, Tiziana's Patent Award
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) Catalent Inc (NYSE: CTLT) CureVac N.V. (NASDAQ: CVAC) ... 
Tags CVAC News Benzinga
From Benzinga
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Are Shareholders Getting a Fair Price?
From GlobeNewswire News Releases
Sanofi Acquiring Principia Biopharma for $3.7 Billion
This isn't the pharmaceutical giant's only recent ride at the acquisition rodeo. 
Tags SNY Market News PRNB
From Motley Fool
PRINCIPIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRNB and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Principia Biopharma Inc. (NASDAQ: PRNB) breached their... 
From Business Wire News Releases
PRINCIPIA BIOPHARMA INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
From GlobeNewswire News Releases
Sanofi To Purchase Immune System-Focused Drugmaker Principia Biopharma For $3.7B
Sanofi SA will acquire Principia Biopharma Inc for $3.68 billion in cash, the two companies announced Monday. 
Tags Stocks / Equities Pharma/Biotech Healthcare
From Blogs - TalkMarkets
Sanofi To Acquire Partner Principia Biopharma, Expand MS Treatment Efforts
Sanofi is expanding efforts to combat MS and other autoimmune diseases by announcing a $3.68 billion acquisition of partner Principia Biopharma. 
From Investor's Business Daily
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc. ("Principia " or the "Company") (NASDAQ: PRNB) breached their... 
From PR Newswire
A Look Into Sanofi's Debt
Over the past three months, shares of Sanofi Inc. (NASDAQ: SNY) increased by 7.48%. Before having a look at the importance of debt, ... 
Tags Markets Intraday Update Market News
From Benzinga
Sanofi Acquires Principia Biopharma For $100 Per Share Or $3.68B
Sanofi and Principia Biopharma entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate... 
Tags Pharma/Biotech Stocks / Equities Healthcare
From Blogs - TalkMarkets
A Peek Into The Markets: US Stock Futures Rise Following Prior Week's Gains
Pre-open movers U.S. stock futures traded higher in early pre-market trade, after recording gains in the previous week. The Empire ... 
Tags Global Benzinga News
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback